On the disclosed annual figures, revenue rose from KRW 55.9 billion in 2022 to KRW 59.8 billion in 2023, up 7.0 percent, then fell to KRW 50.7 billion in 2024, down 15.3 percent, and KRW 38.3 billion in 2025, down 24.5 percent.
Operating results ran from an operating loss of KRW 4.32 billion in 2022 to an operating profit of KRW 516 million in 2023, which turned profitable from a loss, then an operating loss of KRW 6.62 billion in 2024, a swing back into loss, and an operating loss of KRW 6.72 billion in 2025, with the loss persisting and widening.
The operating margin moved from -7.7 percent in 2022 to 0.9 percent in 2023, -13.1 percent in 2024 and -17.6 percent in 2025, so losses grew relative to sales as revenue shrank.
In 2025 the operating loss stayed near the prior-year level even as revenue fell 24.5 percent, which suggests costs did not fall in step with sales.
Net loss attributable to controlling shareholders was KRW 4.33 billion in 2022, KRW 6.7 billion in 2023, KRW 41 billion in 2024 and KRW 7.72 billion in 2025, a loss that persisted in each of the four years from 2022 to 2025.
The 2024 attributable loss of KRW 41 billion was far larger than the KRW 6.62 billion operating loss, pointing to a large non-operating drag. Total net income including non-controlling interests followed the same pattern.
The debt ratio was 57.8 percent in 2022, 156.6 percent in 2023, 49.7 percent in 2024 and 55.8 percent in 2025, when total equity was KRW 90.9 billion and total liabilities KRW 50.7 billion.
Operating cash flow went from KRW 15.7 billion in 2022 to outflows of KRW 3.66 billion in 2023, KRW 6.45 billion in 2024 and KRW 2.7 billion in 2025.
In the quarters, revenue was KRW 7.9 billion in Q3 2025 with an operating loss of KRW 2.44 billion, then KRW 15.5 billion in Q4 2025, up 95.7 percent quarter on quarter, with an operating profit of KRW 342 million.
Q1 2026 revenue was KRW 7.36 billion, down 52.4 percent, with an operating loss of KRW 3.06 billion, followed by KRW 10.7 billion of revenue and an operating loss of KRW 2.75 billion in Q2 2026. Q3 2026 revenue was KRW 8.99 billion, up 13.7 percent year on year, while the operating loss widened to KRW 3.83 billion.
Net income attributable to controlling shareholders was positive in Q4 2025 at KRW 17.9 billion and in Q2 2026 at KRW 11.2 billion, and the last four quarters totaled KRW 14.4 billion.
Press reports attribute the first-half 2026 profit to an impairment reversal of KRW 19.6 billion on the affiliate AriBio stake, and say the pre-tax result excluding that reversal was a loss of about KRW 16.5 billion. Revenue growth in Q3 2026 alongside a wider operating loss shows that core profitability has not yet recovered.